Literature DB >> 3838317

Modulation of heparin cofactor II activity by histidine-rich glycoprotein and platelet factor 4.

D M Tollefsen, C A Pestka.   

Abstract

Heparin cofactor II is a plasma protein that inhibits thrombin rapidly in the presence of either heparin or dermatan sulfate. We have determined the effects of two glycosaminoglycan-binding proteins, i.e., histidine-rich glycoprotein and platelet factor 4, on these reactions. Inhibition of thrombin by heparin cofactor II and heparin was completely prevented by purified histidine-rich glycoprotein at the ratio of 13 micrograms histidine-rich glycoprotein/microgram heparin. In contrast, histidine-rich glycoprotein had no effect on inhibition of thrombin by heparin cofactor II and dermatan sulfate at ratios of less than or equal to 128 micrograms histidine-rich glycoprotein/microgram dermatan sulfate. Removal of 85-90% of the histidine-rich glycoprotein from plasma resulted in a fourfold reduction in the amount of heparin required to prolong the thrombin clotting time from 14 s to greater than 180 s but had no effect on the amount of dermatan sulfate required for similar anti-coagulant activity. In contrast to histidine-rich glycoprotein, purified platelet factor 4 prevented inhibition of thrombin by heparin cofactor II in the presence of either heparin or dermatan sulfate at the ratio of 2 micrograms platelet factor 4/micrograms glycosaminoglycan. Furthermore, the supernatant medium from platelets treated with arachidonic acid to cause secretion of platelet factor 4 prevented inhibition of thrombin by heparin cofactor II in the presence of heparin or dermatan sulfate. We conclude that histidine-rich glycoprotein and platelet factor 4 can regulate the antithrombin activity of heparin cofactor II.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3838317      PMCID: PMC423524          DOI: 10.1172/JCI111725

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  31 in total

1.  Characterization of a chondroitin 4 -sulfate proteoglycan carrier for heparin neutralizing activity (platelet factor 4 ) released from human blood platelets.

Authors:  A J Barber; R Käser-Glanzmann; M Jakábová; E F Lüscher
Journal:  Biochim Biophys Acta       Date:  1972-12-29

2.  Identification of two distinct heparin cofactors in human plasma. Separation and partial purification.

Authors:  G F Briginshaw; J N Shanberge
Journal:  Arch Biochem Biophys       Date:  1974-04-02       Impact factor: 4.013

3.  Identification of two distinct heparin cofactors in human plasma. II. Inhibition of thrombin and activated factor X.

Authors:  G F Briginshaw; J N Shanberge
Journal:  Thromb Res       Date:  1974-03       Impact factor: 3.944

4.  Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies.

Authors:  C B Laurell
Journal:  Anal Biochem       Date:  1966-04       Impact factor: 3.365

5.  Characterization of human, bovine, and horse antithrombin III.

Authors:  K Kurachi; G Schmer; M A Hermodson; D C Teller; E W Davie
Journal:  Biochemistry       Date:  1976-01-27       Impact factor: 3.162

6.  Localization of a chemotactic domain in human thrombin.

Authors:  R Bar-Shavit; A Kahn; M S Mudd; G D Wilner; K G Mann; J W Fenton
Journal:  Biochemistry       Date:  1984-01-31       Impact factor: 3.162

7.  Purification and binding properties of human platelet factor four.

Authors:  R I Handin; H J Cohen
Journal:  J Biol Chem       Date:  1976-07-25       Impact factor: 5.157

8.  Human platelet factor 4: Purification and characterization by affinity chromatography. Purification of human platelet factor 4.

Authors:  S P Levine; H Wohl
Journal:  J Biol Chem       Date:  1976-01-25       Impact factor: 5.157

9.  Induction of the platelet release reaction by phytohemagglutinin.

Authors:  D M Tollefsen; J R Feagler; P W Majerus
Journal:  J Clin Invest       Date:  1974-01       Impact factor: 14.808

10.  Mitogenic activity of blood components. I. Thrombin and prothrombin.

Authors:  L B Chen; J M Buchanan
Journal:  Proc Natl Acad Sci U S A       Date:  1975-01       Impact factor: 11.205

View more
  4 in total

1.  Inhibition of antithrombin by Plasmodium falciparum histidine-rich protein II.

Authors:  Matthew Ndonwi; Oname O Burlingame; Aaron S Miller; Douglas M Tollefsen; George J Broze; Daniel E Goldberg
Journal:  Blood       Date:  2011-04-21       Impact factor: 22.113

Review 2.  The haemostatic function of the vascular endothelial cell.

Authors:  H A Bull; S J Machin
Journal:  Blut       Date:  1987-08

Review 3.  Glycosaminoglycan Neutralization in Coagulation Control.

Authors:  Amélie I S Sobczak; Samantha J Pitt; Alan J Stewart
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-04-19       Impact factor: 8.311

Review 4.  Influence of zinc on glycosaminoglycan neutralisation during coagulation.

Authors:  Amélie I S Sobczak; Samantha J Pitt; Alan J Stewart
Journal:  Metallomics       Date:  2018-09-19       Impact factor: 4.526

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.